Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies. Issue 18 (24th July 2019)

• Record Type: Journal Article
• Authors: Pesarrodona, Mireia; Jauset, Toni; Díaz‐Riascos, Zamira V.; Sánchez‐Chardi, Alejandro; Beaulieu, Marie‐Eve; Seras‐Franzoso, Joaquin; Sánchez‐García, Laura; Baltà‐Foix, Ricardo; Mancilla, Sandra; Fernández, Yolanda; Rinas, Ursula; Schwartz, Simó; Soucek, Laura; Villaverde, Antonio; Abasolo, Ibane; Vázquez, Esther
• Is Part Of: Advanced science. Volume 6:Issue 18(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-07-24
• Subjects: biofabrication -- cancer therapy -- functional amyloids -- inclusion bodies -- protein drug release; Science -- Periodicals; 505
• DOI: 10.1002/advs.201900849
• Languages: English
• ISSNs: 2198-3844

Abstract

Abstract: Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44‐targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types of protein materials selectively penetrate and kill CD44 + tumor cells in culture, and upon local administration, promote destruction of tumoral tissue in orthotropic mouse models of human breast cancer. These findings support the concept of bacterial inclusion bodies as versatile protein materials suitable for application in chronic diseases that, like cancer, can benefit from a local slow release of therapeutic proteins. Abstract : Bacterial inclusion bodies formed by modular proteins are engineered as powerful antitumoral agents for the local administration and treatment of human breast cancer. Targeted to CD44 + cells, such protein materials exhibit a significant antitumor effect in vivo, and show promise as novel functional materials with clinical applicability.